The release today could indicate one of two things:
Either they will be getting FDA approval this year (I still think it won't be until next year). Then the stock will most likely be high enough not to need a reverse split (especially if one of the European countries gives them approval for OTC).
The other option would be to review their stock price at the end of Q1 next year (if they don't get FDA approval). Based on the price of the stock, will determine the ratio of the RS.
At this price point it wouldn't make much sense to do a 1/10 RS. The number of shares outstanding would be too low. JMO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.